Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation
| Autor: | Adrian Podmore, Jack E. Bramham, Alexander P. Golovanov, Stephanie A. Davies |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.drug_class
Chemistry Pharmaceutical Immunology Liquid-Liquid Extraction Ultrafiltration Excipient Fraction (chemistry) Monoclonal antibody Proof of Concept Study Aggregation NMR spectroscopy Report medicine Immunology and Allergy Liquid liquid Humans Reduced viscosity mAb stability Chromatography Chemistry Protein Stability bioprocessing Antibodies Monoclonal Nuclear magnetic resonance spectroscopy liquid-liquid phase separation Dilution Pharmaceutical Solutions medicine.drug |
| Zdroj: | mAbs article-version (VoR) Version of Record |
| ISSN: | 1942-0870 |
| Popis: | Subcutaneous injection of a low volume (100 mg/mL) formulation is an attractive administration strategy for monoclonal antibodies (mAbs) and other biopharmaceutical proteins. Using concentrated solutions may also be beneficial at various stages of bioprocessing. However, concentrating proteins by conventional techniques, such as ultrafiltration, can be time consuming and challenging. Isolation of the dense fraction produced by macroscopic liquid–liquid phase separation (LLPS) has been suggested as a means to produce high-concentration solutions, but practicality of this method, and the stability of the resulting protein solution have not previously been demonstrated. In this proof-of-concept study, we demonstrate that LLPS can be used to concentrate a mAb solution to >170 mg/mL. We show that the structure of the mAb is not altered by LLPS, and unperturbed mAb is recoverable following dilution of the dense fraction, as judged by 1H nuclear magnetic resonance spectroscopy. Finally, we show that the physical properties and stability of a model high concentration protein formulation obtained from the dense fraction can be improved, for example through the addition of the excipient arginine·glutamate. This results in a stable high-concentration protein formulation with reduced viscosity and no further macroscopic LLPS. Concentrating mAb solutions by LLPS represents a simple and effective technique to progress toward producing high-concentration protein formulations for bioprocessing or administration. Abbreviations Arginine·glutamate (Arg·Glu), Carr-Purcell-Meiboom-Gill (CPMG), critical temperature (TC), high-performance size-exclusion chromatography (HPSEC), liquid–liquid phase separation (LLPS), monoclonal antibody (mAb), nuclear magnetic resonance (NMR), transverse relaxation rate (R2) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|